Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Waksal HarlanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:275,000Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Palasis MariaOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:500,000Price:--
-
Jan 30, 2024 (filed on Feb 01, 2024)Insider Name:Bishop John EOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 30, 2024 (filed on Feb 01, 2024)Insider Name:Nieman RichardOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 30, 2024 (filed on Feb 01, 2024)Insider Name:Cavalier JasonOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Nov 10, 2023 (filed on Nov 13, 2023)Insider Name:Waksal HarlanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:25,000Price:$2.96
-
Jun 30, 2023 (filed on Jul 05, 2023)Insider Name:Tobin James ROwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Jun 30, 2023 (filed on Jul 05, 2023)Insider Name:Smith W BradfordOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Jun 30, 2023 (filed on Jul 05, 2023)Insider Name:Poukalov KonstantinOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Jun 30, 2023 (filed on Jul 05, 2023)Insider Name:Altman Michael SethOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
Filings by filing date
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Waksal HarlanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:275,000Price:--
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Palasis MariaOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:500,000Price:--
-
Jan 30, 2024 (filed on Feb 01, 2024)Insider Name:Bishop John EOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 30, 2024 (filed on Feb 01, 2024)Insider Name:Nieman RichardOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 30, 2024 (filed on Feb 01, 2024)Insider Name:Cavalier JasonOwnership Type:Direct OwnershipSecurities:Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Nov 10, 2023 (filed on Nov 13, 2023)Insider Name:Waksal HarlanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:25,000Price:$2.96
-
Jun 15, 2023 (filed on Jul 12, 2023)Insider Name:Palasis MariaOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Jun 30, 2023 (filed on Jul 05, 2023)Insider Name:Tobin James ROwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Jun 30, 2023 (filed on Jul 05, 2023)Insider Name:Smith W BradfordOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Jun 30, 2023 (filed on Jul 05, 2023)Insider Name:Poukalov KonstantinOwnership Type:Direct OwnershipSecurities:Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 480 Arsenal Way WATERTOWN MA 02472 |
Tel: | N/A |
Website: | https://lyratherapeutics.com |
IR: | See website |
Key People | ||
Harlan W. Waksal Executive Chairman of the Board | Maria Palasis President, Chief Executive Officer, Director | Jason Cavalier Chief Financial Officer, Treasurer, Secretary |
Corinne Noyes Senior Vice President - Commercial Strategy and Market Development | Robert Richard Senior Vice President - Technical Operations | John E. Bishop Chief Technology Officer |
Richard Nieman Chief Medical Officer | Ronan O'Brien Chief Legal Officer |
Business Overview |
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery. |
Financial Overview |
For the fiscal year ended 31 December 2023, Lyra Therapeutics Inc revenues increased 14% to $1.6M. Net loss increased 13% to $62.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 23% to $46.9M (expense), General and administrative - Balancing increase of 11% to $14.3M (expense). |
Employees: | 88 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $287.37M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.56M as of Dec 31, 2023 |
EBITDA (TTM): | -$65.24M as of Dec 31, 2023 |
Net annual income (TTM): | -$62.68M as of Dec 31, 2023 |
Free cash flow (TTM): | -$64.35M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 59,743,123 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |